Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process development

18 Feb 2024

Abstract excerpt

Abstract Innovations in viral vaccine manufacturing are crucial for pandemic preparedness and to meet ever‐rising global demands. For influenza, however, production still mainly relies on technologies established decades ago. Although modern production shifts from egg‐based towards cell culture technologies, the full potential has not yet been fully exploited. Here, we evaluate whether implementation of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Viral Infectious Diseases and Gene Expression in Insects
Share to Virus-based gene therapy research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38584687
DOI: 10.1002/elsc.202300245

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

From single‐cell cloning to high‐yield influenza virus production – implementing advanced technologies in vaccine process developmentPMID 38584687Read ↗

Innovations in cell culture-based influenza vaccine manufacturing – from static cultures to high cell density cultivationsSemantic proximity Read ↗

Scalable production of influenza virus in HEK-293 cells for efficient vaccine manufacturingSemantic proximity Read ↗

Accelerating manufacturing to enable large-scale supply of a new adenovirus-vectored vaccine within 100 daysSemantic proximity Read ↗

Designing cell lines for viral vaccine production: Where do we stand?Semantic proximity Read ↗

Critical assessment of influenza VLP production in Sf9 and HEK293 expression systemsSemantic proximity Read ↗

Platforms, advances, and technical challenges in virus-like particles-based vaccinesSemantic proximity Read ↗

Process intensification strategies toward cell culture‐based high‐yield production of a fusogenic oncolytic virusSemantic proximity Read ↗

Cell culture-derived influenza vaccines from Vero cells: a new horizon for vaccine productionSemantic proximity Read ↗

Reshaping Cell Line Development and CMC Strategy for Fast Responses to Pandemic OutbreakSemantic proximity Read ↗

Towards a scalable bioprocess for rAAV production using a HeLa stable cell lineSemantic proximity Read ↗

Translating Innovation to Clinic: End-to-End Bioprocess Development and cGMP Manufacturing of N332-GT5 HIV Vaccine Candidate for First-in-Human Trials HVTN144Semantic proximity Read ↗

A scalable downstream process for the purification of the cell culture-derived Orf virus for human or veterinary applicationsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.